CADL
Candel Therapeutics, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$8.33Close
$457.3MMarket cap
$4.42 – $13.7552-week range
Nov 12, 2026Next report
Highlights
Cautions
- Not in an uptrend 5 of 8 trend conditions
- Far from its high 39% below its 52-week high
- Distribution down-day volume 1.9× up-day volume over 50 sessions
- Results soon Nov 12, 2026, in 11 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
39%
1wk
up 3.7%
price change
1mo
down 20.2%
price change
12-month return
up 49%
market up 11% ·
its own up 41%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
8.8×
price / book
Earnings yield
down 12.6%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 65%
return on equity
Free cash margin
—
-$38.9M FCF
D/E
0.89
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Trade setup
ATR%
6.8%
$0.57 a day · 2×ATR $7.20
RS
74 / 99
vs the universe
Trend
5 / 8
under the 150/200-day, under the 50-day, over 25% off the high
Relative volume
0.7×
vs 50-day average
Up/down volume
0.53
50 sessions
Implied move
—
no option chain · report Nov 12, 2026
Trend template · 5 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 17.3% over the year, from 47m to 55m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 13, 2026
Results reaction
Aug 13, 2026+9% vs market2 sessions after results
Financials
- Net
- Free cash
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $125,000 | $125,000 | $125,000 | — | — | — |
| Operating income | -$13.8M | -$25.7M | -$34.7M | -$38.4M | -$33.4M | -$48.3M |
| Net income | -$17.7M | -$36.1M | -$18.8M | -$37.9M | -$55.2M | -$38.2M |
| Net margin | -14144% | -28899% | -15035% | — | — | — |
| Earnings per share | — | -$1.91 | -$0.65 | -$1.31 | -$1.74 | -$0.72 |
| Free cash flow | -$10.5M | -$24.1M | -$32.7M | -$34.7M | -$27.0M | -$38.9M |
| Free cash margin | -8438% | -19242% | -26173% | — | — | — |
| Cash | $35.1M | $82.6M | $70.1M | $35.4M | $102.7M | $119.7M |
| Long-term debt | $483,000 | $560,000 | — | $11.6M | $1.7M | $46.1M |
| Shareholders' equity | -$23.6M | $64.1M | $47.7M | $12.7M | $66.3M | $51.9M |
| Shares outstanding | 11.64m | 28.69m | 28.92m | 29.09m | 46.81m | 54.90m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 13, 2026 | Quarterly ↗ | Jun 30, 2026 | 44d |
| May 14, 2026 | Quarterly ↗ | Mar 31, 2026 | 44d |
| Mar 12, 2026 | Annual ↗ | Dec 31, 2025 | 71d |
| Nov 13, 2025 | Quarterly ↗ | Sep 30, 2025 | 44d |
| Aug 14, 2025 | Quarterly ↗ | Jun 30, 2025 | 45d |
| May 13, 2025 | Quarterly ↗ | Mar 31, 2025 | 43d |
| Mar 13, 2025 | Annual ↗ | Dec 31, 2024 | 72d |
| Nov 14, 2024 | Quarterly ↗ | Sep 30, 2024 | 45d |
| Aug 13, 2024 | Quarterly ↗ | Jun 30, 2024 | 44d |
| May 14, 2024 | Quarterly ↗ | Mar 31, 2024 | 44d |
| Mar 28, 2024 | Annual ↗ | Dec 31, 2023 | 88d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 10, 2026 | Director or officer change · Regulation FD ↗ |
| Sep 9, 2026 | Regulation FD ↗ |
| Aug 13, 2026 | Results ↗ |
| Jun 24, 2026 | Shareholder vote ↗ |
| Jun 16, 2026 | Director or officer change ↗ |
| May 15, 2026 | Regulation FD ↗ |
| May 14, 2026 | Results ↗ |
| Mar 12, 2026 | Results ↗ |
| Feb 23, 2026 | Material agreement · Other events ↗ |
| Feb 19, 2026 | Material agreement · Results · Regulation FD · Other events ↗ |
| Dec 5, 2025 | Regulation FD ↗ |
| Nov 13, 2025 | Results ↗ |